Faron Pharmaceuticals: Updated BEXMAB data from ESMO 2025 shows further improvements - Redeye

Redeye comments on Faron’s updated BEXMAB data presented at the ESMO 2025 congress, which further strengthens the clinical and mechanistic foundation of bexmarilimab in high-risk myelodysplastic syndrome (HR-MDS). The data showed an improved 85% overall response rate and 45% complete remission rate in treatment-naïve patients, alongside a clear pharmacodynamic correlation between Clever-1 target engagement and clinical outcomes.

Länk till analysen i sin helhet: https://www.redeye.se/research/1131338/faron-pharmaceuticals-updated-bexmab-data-from-esmo-2025-shows-further-improvements?utm_source=finwire&utm_medium=RSS